[{"address1": "230 Park Avenue", "address2": "Suite 3350", "city": "New York", "state": "NY", "zip": "10169", "country": "United States", "phone": "646 885 8505", "website": "https://www.ymabs.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. The company is also developing DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumor; and Omburtamab, a murine monoclonal antibody for the treatment of central nervous system/leptomeningeal metastases from neuroblastoma, as well as SADA PRIT technology platform. In addition, it is engages in the developing of CD38-SADA and GD2-GD3 Vaccine. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.", "fullTimeEmployees": 100, "companyOfficers": [{"maxAge": 1, "name": "Mr. Thomas  Gad", "age": 53, "title": "Founder, Chief Business Officer & Vice Chairman", "yearBorn": 1970, "fiscalYear": 2022, "totalPay": 1047496, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Bo  Kruse", "age": 50, "title": "Executive VP, Secretary, Treasurer & CFO", "yearBorn": 1973, "fiscalYear": 2022, "totalPay": 685021, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Susan  Smith", "age": 52, "title": "Senior VP & Chief Commercial Officer", "yearBorn": 1971, "fiscalYear": 2022, "totalPay": 710000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Michael  Rossi", "age": 52, "title": "CEO, President & Director", "yearBorn": 1971, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Joris Wiel Jan Wilms", "age": 49, "title": "Senior VP & COO", "yearBorn": 1974, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Torben  Lund-Hansen M.Sc., Ph.D.", "age": 72, "title": "Senior VP & CTO", "yearBorn": 1951, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Steen  Lisby M.D., M.Sc.", "age": 59, "title": "Senior VP & Chief Scientific Officer", "yearBorn": 1964, "fiscalYear": 2022, "totalPay": 393985, "exercisedValue": 0, "unexercisedValue": 274400}, {"maxAge": 1, "name": "Ms. Courtney  Dugan", "title": "Vice President of Investor Relations", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Vignesh  Rajah M.B.A., MBBS", "age": 58, "title": "Senior VP & Chief Medical Officer", "yearBorn": 1965, "fiscalYear": 2022, "totalPay": 406275, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 4, "boardRisk": 8, "compensationRisk": 9, "shareHolderRightsRisk": 8, "overallRisk": 8, "governanceEpochDate": 1709251200, "compensationAsOfEpochDate": 1672444800, "maxAge": 86400, "priceHint": 2, "previousClose": 15.49, "open": 15.74, "dayLow": 15.74, "dayHigh": 17.26, "regularMarketPreviousClose": 15.49, "regularMarketOpen": 15.74, "regularMarketDayLow": 15.74, "regularMarketDayHigh": 17.26, "beta": 0.746, "forwardPE": -49.823532, "volume": 358585, "regularMarketVolume": 358585, "averageVolume": 408828, "averageVolume10days": 343590, "averageDailyVolume10Day": 343590, "bid": 16.92, "ask": 16.96, "bidSize": 100, "askSize": 100, "marketCap": 741584128, "fiftyTwoWeekLow": 2.7, "fiftyTwoWeekHigh": 20.9, "priceToSalesTrailing12Months": 8.743137, "fiftyDayAverage": 13.9858, "twoHundredDayAverage": 8.0525, "currency": "USD", "enterpriseValue": 664366144, "profitMargins": -0.25261998, "floatShares": 27555937, "sharesOutstanding": 43777100, "sharesShort": 2173588, "sharesShortPriorMonth": 2253027, "sharesShortPreviousMonthDate": 1706659200, "dateShortInterest": 1709164800, "sharesPercentSharesOut": 0.0497, "heldPercentInsiders": 0.14545, "heldPercentInstitutions": 0.61882, "shortRatio": 4.84, "shortPercentOfFloat": 0.0596, "bookValue": 2.312, "priceToBook": 7.3269897, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1703980800, "netIncomeToCommon": -21427000, "trailingEps": -0.49, "forwardEps": -0.34, "pegRatio": 0.37, "enterpriseToRevenue": 7.833, "enterpriseToEbitda": -32.479, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "YMAB", "underlyingSymbol": "YMAB", "shortName": "Y-mAbs Therapeutics, Inc.", "longName": "Y-mAbs Therapeutics, Inc.", "firstTradeDateEpochUtc": 1537536600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "ef4c7aed-ff51-3117-8a16-0b2c87e3c948", "gmtOffSetMilliseconds": -14400000, "currentPrice": 16.94, "targetHighPrice": 26.0, "targetLowPrice": 10.0, "targetMeanPrice": 20.0, "targetMedianPrice": 22.0, "recommendationMean": 2.1, "recommendationKey": "buy", "numberOfAnalystOpinions": 7, "totalCash": 78637000, "totalCashPerShare": 1.796, "ebitda": -20455000, "totalDebt": 1419000, "quickRatio": 5.022, "currentRatio": 5.52, "totalRevenue": 84819000, "debtToEquity": 1.405, "revenuePerShare": 1.943, "returnOnAssets": -0.09835, "returnOnEquity": -0.20387, "freeCashflow": -14034750, "operatingCashflow": -27232000, "revenueGrowth": -0.257, "grossMargins": 0.86541003, "ebitdaMargins": -0.24115999, "operatingMargins": -0.13693, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-03-22"}]